CohBar's lead candidate may initiate clinical trials in 2022
Longevity Technology - 16-Mar-2021Mitochondrial-based therapy enters IND to tackle IPF and other fibrotic diseases
Join the club for FREE to access the whole archive and other member benefits.
Chief Executive Officer & Director, CohBar
Steven Engle joined CohBar as Chief Executive Officer and Director in 2019. From 2011 to 2019, he served as the Chief Executive Officer of Averigon, an advisory firm to the life science industry. From 2007 to 2011, Mr. Engle was Chairman, Chief Executive Officer and President of XOMA Corporation. From 1993 to 2006, he held several executive management roles including serving as Chairman and Chief Executive Officer at La Jolla Pharmaceutical Company. Mr. Engle is chairman of Prescient Therapeutics and a director on the boards of AROA Biosurgery and Author-it Software Corporation. He is a former director of the board of the industry associations, BIO, BayBio and BIOCOM. Mr. Engle received a B.S. and M.S. in Electrical Engineering from the University of Texas, Austin.
Visit website: https://www.bloomberg.com/profile/person/1403357
See also: CohBar - Company focused on the research and development of mitochondria based therapeutics.
Details last updated 19-Mar-2021
11-Oct-2021 to 14-Oct-2021
The Kitalys institute virtual conference targeting key questions that will impact the future of aging and extending healthspan
Mitochondrial-based therapy enters IND to tackle IPF and other fibrotic diseases